Loading...
Loading...
- Veradigm Inc MDRX shares are trading higher Wednesday after the company announced a new share repurchase program under which Veradigm may purchase up to $250 million of its common stock.
- The new share repurchase program does not have a termination date and replaces the previous authorization to repurchase $250 million of common stock, which was almost fully utilized in 2022.
- In the fourth quarter of 2022, Veradigm repurchased $57 million of its common stock, bringing its full-year total to $234 million.
- The company also introduced initial FY23 revenue guidance of $640 million and $660 million, compared to the consensus of $656.84 million.
- Veradigm expects adjusted EPS of $0.90 and $1.00 versus the consensus of $0.95.
- Last week, Allscripts Healthcare Solutions Inc changed its name to Veradigm Inc. Allscripts had been transitioning its solutions to the Veradigm brand during 2022.
- Price Action: MDRX shares are up 3% at $18.35 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in